Risk-Based Process Validation (QbD, Design Space, CPPs & CQAs)

Documentation of Risk Assessments and QbD Studies for Regulatory Review Documentation of Risk Assessments and QbD Studies for Regulatory Review In the highly regulated pharmaceutical industry, the documentation of Quality by Design (QbD) and associated risk assessments is critical for achieving compliance and facilitating the acceptance of submissions by regulatory agencies such as the FDA, EMA, and MHRA. This tutorial…

Integrating Risk Based Process Validation Into Site Validation Master Plans In the ever-evolving landscape of pharmaceutical manufacturing, regulatory expectations regarding validation practices have steadily advanced, with a focus on ensuring product quality and patient safety. This article aims to provide a comprehensive overview of how to incorporate risk-based process validation into Validation Master Plans (VMPs), addressing the key elements as…

Inspection Questions on QbD and Risk Based Validation What to Expect Introduction to Quality by Design (QbD) and Risk-Based Validation In today’s highly regulated pharmaceutical environment, Quality by Design (QbD) and risk-based validation stand as pivotal concepts aimed at enhancing product quality and process efficiency. Understanding how to prepare for inspections focusing on these areas is essential for pharmaceutical professionals….

Using Risk Based Approaches to Decide When Revalidation Is Required Using Risk Based Approaches to Decide When Revalidation Is Required Introduction to Risk-Based Revalidation Decisions Validation in the pharmaceutical sector is a critical activity mandated to ensure that processes, systems, and equipment operate as intended and produce quality products consistently. Regulatory bodies such as the FDA, the European Medicines Agency…